2 min read

Cleerly Appoints Joseph Jasser, MD, as Chief of Value Based Care

Cleerly Appoints Joseph Jasser, MD, as Chief of Value Based Care

Heart Health Innovator Cleerly Appoints Joseph Jasser, MD, as Chief of Value Based Care
Hire follows Cleerly's $223 million Series C and furthers value-based care business strategy


 

New York – August 15, 2022 -- Cleerly, the company creating a new standard of care for heart disease, announced it has appointed Joseph "Joe" Jasser, MD, as chief of value based care. In this role, Dr. Jasser will be responsible for developing and executing the initial business plan and go-to-market strategy for the value-based care client segment. He will also lead the commercial and client services teams for Cleerly's Value Based Care vertical, and will report to Jim Hartman, chief revenue officer of Cleerly.

"I'm very excited to have Joe join us on our mission to create a world without heart attacks," Hartman said. "His knowledge of and passion for designing tailored solutions to provide an excellent patient experience, while also optimizing the clinical and financial outcomes of a value-based care model for clients, makes him a natural fit for the Cleerly team. Joe has impressive experience as a builder of highly successful value-based care models – whether he's working in a health system, health plan or business-to-business organization within the healthcare industry."

Prior to joining Cleerly, Dr. Jasser was chief medical officer of Vesta Healthcare and previously, he was the Chief Medical Officer of bclinical, PLLC where he provided clinical consultative services for clinical delivery organizations and medical groups. He has also served as the chief medical officer and executive vice president of Complex Care Management at Signify Health and was the president of care delivery for Humana, Inc. Additionally, Dr. Jasser served as the president and CEO of Dignity Health Medical Foundation and held roles at Cigna-HealthSpring, CIGNA and Concentra.

Dr. Jasser earned his Bachelor of Science degree from The Ohio State University, his medical degree from The Ohio State University College of Medicine and an Executive Master of Business Administration from Washington State University. He completed his residency at Summa Health System and is board certified in internal medicine.

"I'm excited about what Cleerly can and will do for cardiovascular disease; it's disruptive and revolutionary," Dr. Jasser said. "I look forward to building Cleerly's value-based care client segment with a variety of solutions for health plans and providers that offer a new, improved standard of cardiovascular care to patients."

This appointment comes after Cleerly's recently announced Series C funding round of $223 million led by T. Rowe Price and Fidelity.

 


 

About Cleerly

Cleerly is the company creating a new standard of care for heart disease. Through its FDA-cleared, value-based diagnostic solutions driven by machine intelligence, Cleerly enables comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: https://www.cleerlyhealth.com.

Cleerly Press Contact:

press@cleerlyhealth.com

 


 

Resources
Cleerly Appoints Joseph Jasser, MD | Announcement

Download: JPG

Cleerly Appoints Joseph Jasser, MD | Headshot

Download: JPG

Cleerly wordmark: full color (thumbnail)

Download: PNG | EPS

Cleerly wordmark: white (thumbnail)

Download: PNG | EPS

Cleerly iconmark: full color (thumbnail)

Download: PNG | EPS

Cleerly iconmark: white (thumbnail)

Download: PNG | EPS

View more media resources ⇢

Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials

Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials

CREDENCE and PACIFIC-1 study data demonstrate potential power of AI-QCT ISCHEMIA

Read More
Cleerly® Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System

Cleerly® Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System

Company’s AI-enabled technology for future heart attack risk assessment accepted into FDA’s TAP Pilot and to be validated in landmark TRANSFORM trial

Read More
Cleerly® ISCHEMIA™ Software Device Billable With AMA Category I CPT® Code for Noninvasive Estimates of Fractional Flow Reserve

Cleerly® ISCHEMIA™ Software Device Billable With AMA Category I CPT® Code for Noninvasive Estimates of Fractional Flow Reserve

FDA-cleared Cleerly ISCHEMIA will assist healthcare professionals in clinical diagnosis and decision making for coronary artery disease

Read More